Listed times are in Central European Time (CET)

WELCOME TO DAY ONE

Chair: Rene Bernards

Matheus Dias NKI, Netherlands

'Therapeutic OVERactivation of oncogenic signalling as a cancer treatment strategy'

Q&A: 12:25-12:35

Chrysa Papagianni Netherlands Cancer Institute, Netherlands

Proffered Paper 1: 'Overactivation of oncogenic signaling steers cancer cells towards less malignant phenotypes'

Q&A: 12:45-12:50

Dylan Farnsworth BC Cancer Research Institute, Canada

Proffered Paper 2: 'Disrupting proteostasis potentiates ERK hyperactivation in LUAD'

Q&A: 13:00-13:05

Vesselina Cooke Novartis, USA

'Small Molecule-induced ERK Hyperactivation as a Novel Therapeutic Approach for BRAF V600-Mutant Melanoma'

Q&A: 13:25-13:35

REFRESHMENT BREAK

Chair: Bart Vanhaesebroeck

FLASH TALKS 1

A selection of high-scoring abstracts presented as 3 minute flash talks.

Monica Roman-Trufero Lausanne University Hospital, Switzerland

Proffered Paper 3: 'GCN2 loss drives translational overdrive and metabolic collapse, creating a targetable cancer vulnerability'

Q&A: 14:15-14:20

Arun Unni Weill Cornell Medicine, USA

'Understanding the consequences of excess RAS pathway activity in cancer cells'

Q&A: 14:40-14:50

REFRESHMENT BREAK

Pia Giovannelli University of Campania Luigi Vanvitelli, Italy

Proffered Paper 4: 'Androgen Receptor Paradox: Overactivation of ERK Inhibits HRPC Growth'

Q&A: 15:15-15:20

Marta Rubin University of Turin, Italy

Proffered Paper 5: 'Hyperactivation of ALK signaling triggered by PTPN2/PTPN1 pharmacologic inhibition induces oncogenic stress responses to promote tumor eradication in ALK-positive lymphoma'

Q&A: 15:30-15:35

Closing Keynote

Markus Müschen Yale School of Medicine, USA

'Hyperactivation of oncogenic STAT5-signaling as treatment strategy for tyrosine kinase-driven leukemia'

Q&A: 16:05-16:20

SUMMARY AND CLOSE

Listed times are in Central European Time (CET)

WELCOME TO DAY TWO

Chair: Bart Vanhaesebroeck

Benoit Bilanges UCL Cancer Institute, UK

'Pharmacological activation of PI3Kα triggers cancer cell death under metabolic stress'

Q&A: 12:25-12:35

Marina Baessa IPATIMUP / i3s, Portugal

Proffered Paper 6: 'Therapeutic T-cell receptor activation in T-cell acute lymphoblastic leukemia'

Q&A: 12:45-12:50

Eunice Cho The Broad Institute, USA

'Directed clonal evolution: Exploiting divergent MAPK inhibitor resistance for convergent hypersensitivity to MAPK hyperactivation'

Q&A: 13:10-13:20

REFRESHMENT BREAK

FLASH TALKS 2

A selection of high-scoring abstracts presented as 3 minute flash talks.

David Santamaria CIC (Cancer Research Center of Salamanca), Spain

Proffered Paper 7: 'MAPK hyper-signalling driven by DUSP4 inactivation modulates the onset and progression of KRAS mutant lung adenocarcinoma'

Q&A: 14:00-14:05

Andrew Intlekofer MSKCC, USA

'Enzyme hyperactivation to target oncometabolism'

Q&A: 14:25-14:35

REFRESHMENT BREAK

Chair: Rene Bernards

Ana Banito German Cancer Research Center (DKFZ), Germany

Proffered Paper 8: 'A dynamic balance between vPRC1 complexes finetunes oncofusion activity in synovial sarcoma'

Q&A: 15:00-15:05

Closing Keynote

Kimberly Stegmaier Dana-Farber Cancer Institute, USA

'EWS::FLI1 Activation Lethality in Ewing Sarcoma'

Q&A 15:35-15:50

DISCUSSION SESSION

Will over activation cause cancer or cure cancer?

CONFERENCE SUMMARY AND CLOSE